Vera Therapeutics (VERA) Expected to Announce Quarterly Earnings on Wednesday

Vera Therapeutics (NASDAQ:VERA) is expected to post its quarterly earnings results before the market opens on Wednesday, March 19th. Analysts expect Vera Therapeutics to post earnings of ($0.81) per share for the quarter.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.11. On average, analysts expect Vera Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Vera Therapeutics Trading Up 0.3 %

Shares of VERA opened at $28.07 on Tuesday. Vera Therapeutics has a 52-week low of $25.99 and a 52-week high of $51.61. The business’s fifty day moving average is $32.73 and its 200-day moving average is $39.58. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of -10.75 and a beta of 1.17.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Wolfe Research assumed coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price target on the stock. Wells Fargo & Company assumed coverage on Vera Therapeutics in a research note on Thursday, November 21st. They issued an “overweight” rating and a $70.00 price target on the stock. The Goldman Sachs Group began coverage on Vera Therapeutics in a research note on Tuesday, January 28th. They issued a “buy” rating and a $58.00 price target on the stock. JPMorgan Chase & Co. cut their price objective on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a report on Tuesday, March 4th. Finally, Guggenheim raised their price objective on Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a report on Thursday, February 27th. One analyst has rated the stock with a hold rating, six have given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $64.67.

Insiders Place Their Bets

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $41.74, for a total transaction of $730,450.00. Following the transaction, the chief executive officer now directly owns 143,603 shares of the company’s stock, valued at approximately $5,993,989.22. The trade was a 10.86 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 21.70% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.